phosphate for Hypercalciuria

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Hypercalciuria+4 More
phosphate - Drug
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial will look at the effects of different doses and lengths of treatment of a condition called hypophosphatemic rickets with hypercalciuria.

Eligible Conditions
  • Hypercalciuria
  • Hypophosphatemia
  • Rickets
  • HHRH
  • X-linked Hypophosphatemia (XLH)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Hypercalciuria

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 30 days

30 days
Fibroblast Growth Factor 23 (FGF23) levels
Parathyroid Hormone (PTH) levels

Trial Safety

Safety Progress

1 of 3

Other trials for Hypercalciuria

Trial Design

4 Treatment Groups

15 Patients Hereditary hypophosphatemic rickets with HHRH
1 of 4
Patients with X-linked Hypophosphatemia
1 of 4
15 Patients with X-linked Hypophosphatemia
1 of 4
Patients with hereditary hypophosphatemic rickets with HHRH
1 of 4
Active Control
Experimental Treatment

30 Total Participants · 4 Treatment Groups

Primary Treatment: phosphate · No Placebo Group · Phase < 1

Patients with hereditary hypophosphatemic rickets with HHRH
Drug
Experimental Group · 1 Intervention: phosphate · Intervention Types: Drug
15 Patients Hereditary hypophosphatemic rickets with HHRH
Drug
ActiveComparator Group · 1 Intervention: phosphate · Intervention Types: Drug
Patients with X-linked Hypophosphatemia
Drug
ActiveComparator Group · 1 Intervention: phosphate · Intervention Types: Drug
15 Patients with X-linked Hypophosphatemia
Drug
ActiveComparator Group · 1 Intervention: phosphate · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 30 days

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,666 Previous Clinical Trials
21,074,760 Total Patients Enrolled
Clemens Bergwitz, MDPrincipal InvestigatorYale University

Eligibility Criteria

Age Any Age · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are willing to provide access to prior medical records to determine eligibility including imaging, biochemical, medical, and surgical history data.
You are willing to comply with the study schedule and assessments.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 8th, 2021

Last Reviewed: October 20th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.